REGN - リジェネロン・ファ―マシュ―ティカルズ (Regeneron Pharmaceuticals Inc.) リジェネロン・ファ―マシュ―ティカルズ

 REGNのチャート


 REGNの企業情報

symbol REGN
会社名 Regeneron Pharmaceuticals Inc. (リジェネロン・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 リジェネロン・ファーマシューティカルズ(Regeneron Pharmaceuticals Inc)は重症疾患に使われる医薬品の発見・発明・開発・生産・商品化を行うバイオ医薬品会社である。同社は眼疾患、高密度リポタンパク質(LDL)コレステロール、炎症性疾患の医薬品を商品化し、慢性関節リウマチ、喘息、アトピー性皮膚炎、疼痛、がん、感染症などの分野に開発する製品候補を有する。同社は、EYLEA(aflibercept)注射剤、Praluent(アリロクマブ)注射剤、ARCALYST(rilonacept)皮下注射剤、Kevzara(sarilumab)皮下注射剤、ZALTRAP(ziv-aflibercept)注射剤を販売する。   リジェネロン・ファ―マシュ―ティカルズは米国の大手バイオ医薬品会社。主にがん、眼病、炎症に対する治療薬の開発、製造、販売に従事。主要な製品は加齢黄斑変性症と網膜中心静脈閉塞の黄斑浮腫治療薬「EYLEA」、転移性結腸直腸がん治療薬「ZALTRAP」、抗炎症剤「ARCALYST」など。本社はニューヨーク州。   Regeneron Pharmaceuticals Inc is an integrated biopharmaceutical company. It discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.
本社所在地 777 Old Saw Mill River Road Tarrytown NY 10591-6707 USA
代表者氏名 P. Roy Vagelos P. Roy Vagelos
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 914-347-7000
設立年月日 32143
市場名 NASDAQ National Market System
ipoyear 1991年
従業員数 6200人
url www.regeneron.com
nasdaq_url https://www.nasdaq.com/symbol/regn
adr_tso
EBITDA EBITDA(百万ドル) 2430.382
終値(lastsale) 394.17
時価総額(marketcap) 42592570691.16
時価総額 時価総額(百万ドル) 41378.5
売上高 売上高(百万ドル) 6202.627
企業価値(EV) 企業価値(EV)(百万ドル) 40400.885
当期純利益 当期純利益(百万ドル) 1917.428
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Regeneron Pharmaceuticals Inc revenues increased 12% to $3.12B. Net income increased 62% to $1.03B. Revenues reflect Net product sales increase of 11% to $1.98B Bayer Collaboration Revenue increase of 26% to $510.8M Other revenue increase of 16% to $197.2M. Net income benefited from Payroll and Benefits decrease of 4% to $280.7M (expense).

 REGNのテクニカル分析


 REGNのニュース

   Assessing If Regeneron Is In Value Territory After Shares Tumble  2019-05-08
Ahead of first-quarter results, Regeneron ( REGN ) shares fell from the $400-440 level and below its major 50- and 200-day moving averages. When the company failed to meet Wall Street expectations, shares fell another 6%. Sales of its atopic dermatitis drug Dupixent are growing and stand to be…
   Equities Try To Steady After Selloff (Wall Street Breakfast Podcast)  2019-05-08
Today's Top Stories: Equities try to steady after selloff; Iran begins withdrawal from nuclear deal; and pound on edge as support builds to oust May. If you are interested in listening to Wall Street Breakfast to start your day, look for us in the following places: iTunes (find…
   Wall Street Breakfast: Equities Try To Steady After Selloff  2019-05-08
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Stitcher and Spotify (click the highlighted links). Wall Street is looking to stabilize following last night's 473 point fall for the DJIA, as Chinese t…
   Assessing If Regeneron Is In Value Territory After Shares Tumble  2019-05-08
Ahead of first-quarter results, Regeneron ( REGN ) shares fell from the $400-440 level and below its major 50- and 200-day moving averages. When the company failed to meet Wall Street expectations, shares fell another 6%. Sales of its atopic dermatitis drug Dupixent are growing and stand to be…
   Equities Try To Steady After Selloff (Wall Street Breakfast Podcast)  2019-05-08
Today's Top Stories: Equities try to steady after selloff; Iran begins withdrawal from nuclear deal; and pound on edge as support builds to oust May. If you are interested in listening to Wall Street Breakfast to start your day, look for us in the following places: iTunes (find…
   Wall Street Breakfast: Equities Try To Steady After Selloff  2019-05-08
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Stitcher and Spotify (click the highlighted links). Wall Street is looking to stabilize following last night's 473 point fall for the DJIA, as Chinese t…
   FDA Approves Praluent® (alirocumab) to Prevent Heart Attack, Stroke and Unstable Angina Requiring Hospitalization  2019-04-26 PR Newswire
TARRYTOWN, N.Y. and PARIS , April 26, 2019 /PRNewswire/ -- Praluent is the first PCSK9 inhibitor that has shown a meaningful reduction in death from any cause Praluent treatment effect was observed in patients already receiving other lipid-lowering therapies, including maximally…
   Regeneron slips 2% on conditional approval recommendation in Europe for Libtayo  2019-04-26
The European Medicines Agency's advisory group CHMP has adopted a positive opinion backing conditional approval for Regeneron Pharmaceuticals' ( REGN -2% ) Libtayo (cemiplimab) for the treatment of advanced cutaneous squamous cell carcinoma, the second most-common type of skin cance…
   CHMP Issues Positive Opinion for Libtayo® (cemiplimab) in Advanced Cutaneous Squamous Cell Carcinoma  2019-04-26 PR Newswire
TARRYTOWN, N.Y. and PARIS , April 26, 2019 /PRNewswire/ -- - Currently no approved treatments in the European Union for advanced cutaneous squamous cell carcinoma (CSCC) - CSCC is one of the most common skin cancers worldwide Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN …
   Key events next week - healthcare (Part 1)  2019-04-26
Noteworthy events during the week of April 28 - May 4 for healthcare investors. More news on: Catalyst Biosciences, Inc., Aldeyra Therapeutics, Inc., BioTime, Inc., Healthcare stocks news, , Read more …

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 リジェネロン・ファ―マシュ―ティカルズ REGN Regeneron Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)